Apimeds Pharmaceuticals US (APUS) Operating Leases (2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Operating Leases came in at $129454.0 in Q4 2025.
Apimeds Pharmaceuticals US (APUS) Operating Leases (2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 1 years of Operating Leases data on file, last reported at $129454.0 in Q4 2025.
- Quarterly Operating Leases changed N/A year-over-year to $129454.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $129454.0 (changed N/A YoY) and the FY2025 annual result came in at $129454.0, changed N/A from the prior year.
- Operating Leases held at $129454.0 in Q4 2025.
- In the past five years, Operating Leases ranged from a high of $129454.0 in Q4 2025 to a low of $129454.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - |
| 10 | Apimeds Pharmaceuticals US | 7.20 Mn | 7.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 129,454.00 |